MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592411 | Name: Alconil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alconil is a biochemical.

Chemical Structure

Alconil
Alconil
CAS#97677-19-5

Theoretical Analysis

MedKoo Cat#: 592411

Name: Alconil

CAS#: 97677-19-5

Chemical Formula: C15H9FN2O2

Exact Mass: 268.0648

Molecular Weight: 268.25

Elemental Analysis: C, 67.16; H, 3.38; F, 7.08; N, 10.44; O, 11.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Alconil; Al 1567; Al-1567; Al1567
IUPAC/Chemical Name
Spiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione, 2-fluoro-
InChi Key
JRGBXEJDIMXJAP-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H9FN2O2/c16-8-5-6-10-9-3-1-2-4-11(9)15(12(10)7-8)13(19)17-14(20)18-15/h1-7H,(H2,17,18,19,20)
SMILES Code
O=C1NC2(C(N1)=O)C3=C(C4=C2C=CC=C4)C=CC(F)=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 268.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Cartault F, Munier P, Jacquemont ML, Vellayoudom J, Doray B, Payet C, Randrianaivo H, Laville JM, Munnich A, Cormier-Daire V. Expanding the clinical spectrum of B4GALT7 deficiency: homozygous p.R270C mutation with founder effect causes Larsen of Reunion Island syndrome. Eur J Hum Genet. 2015 Jan;23(1):49-53. doi: 10.1038/ejhg.2014.60. Epub 2014 Apr 23. PubMed PMID: 24755949; PubMed Central PMCID: PMC4266744. 2: Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. Ann Clin Biochem. 2003 May;40(Pt 3):219-31. PubMed PMID: 12803832. 3: Lamensdorf I, Eisenhofer G, Harvey-White J, Nechustan A, Kirk K, Kopin IJ. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res. 2000 Jun 23;868(2):191-201. PubMed PMID: 10854571. 4: Brazzell RK, Park YH, Wooldridge CB, McCue B, Barker R, Couch R, York B. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors. Drug Metab Dispos. 1990 Jul-Aug;18(4):435-40. PubMed PMID: 1976064. 5: Park YH, McCue BA, Dobbs RE, York BM, Brazzell RK. High-performance liquid chromatographic assay of the aldose reductase inhibitor spiro-(2-fluoro-9H-fluorene-9,4'-imidazolidine)-2',5'-dione (AL01567) in plasma and urine and its pharmacokinetics in humans. J Pharm Sci. 1988 Jul;77(7):591-5. PubMed PMID: 3139862. 6: Lou MF, Dickerson JE Jr, Garadi R, York BM Jr. Glutathione depletion in the lens of galactosemic and diabetic rats. Exp Eye Res. 1988 Apr;46(4):517-30. PubMed PMID: 3133235. 7: Thomas DM, Mahendroo PP, Lou MF. Dynamic phosphorus-31 NMR study of sugar cataract and its prevention in rat lenses with aldose reductase inhibitors. Exp Eye Res. 1988 Jan;46(1):37-47. PubMed PMID: 3125056. 8: Griffin BW, McNatt LG, Chandler ML, York BM. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats. Metabolism. 1987 May;36(5):486-90. PubMed PMID: 3106757. 9: Ohrloff C, Hockwin O, Korte I, Wegener A. [Aldose reductase inhibitor--a new way for preventing diabetic lens changes?]. Klin Monbl Augenheilkd. 1986 Nov;189(5):361-2. German. PubMed PMID: 3100860. 10: Griffin BW, McNatt LG. Characterization of the reduction of 3-acetylpyridine adenine dinucleotide phosphate by benzyl alcohol catalyzed by aldose reductase. Arch Biochem Biophys. 1986 Apr;246(1):75-81. PubMed PMID: 3083781. 11: Kador PF, Kinoshita JH, Sharpless NE. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J Med Chem. 1985 Jul;28(7):841-9. Review. PubMed PMID: 3925146.